Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

As weight-loss injections emerge as key players in the government’s anti-obesity strategy, Emma Loffhagen goes inside the ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Leigh-Anne Lagden was given a free weight loss injection in exchange for social media promotion but claims they told her to ...

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, ...

Eli Lilly And Co LLY experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs ...